| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
VENLO , The Netherlands—QIAGEN N.V. and Eppendorf AG recently formed a strategic alliance that includes co-development and co-marketing of complementary and optimized products. In general, the alliance is intended to link what the companies call "two of the strongest brands and product lines in the industry" to ensure the highest compatibility of their products in research, applied testing and molecular diagnostics applications.
 
Eppendorf boasts expertise in liquid handling, including automated solutions, as well as corresponding plastic products and instrumentation that impacts life science researchers' entire workflow. QIAGEN, for its part, offers talents in preanalytical sample preparation and has created what it considers to be innovative chemistry- and biology-driven consumables for preanalytical solutions, as well as instrumentation for such consumable products.
 
In addition, QIAGEN acquired Eppendorf's reagent business, which includes the Eppendorf "5-Prime" nucleic acid sample preparation and PCR reagent product lines and related intellectual property. The acquired assets are said to represent a promising pipeline of proprietary technologies for nucleic acid handling, separation, purification and amplification.
 
Both the strategic alliance and the acquisition are in line with QIAGEN's recent business efforts, which have used collaborations, partnerships and a series of acquisitions to secure analytic technologies, particularly those that could impact its sample preparation and polymerase chain reaction (PCR) business.
 
"Real-time PCR is a key technology in the rapidly growing life science research markets, and [with various acquisitions and deals] QIAGEN is now very well positioned as a leading manufacturer and supplier of high-quality PCR reagents and kits in this field," says Peer M. Schatz, QIAGEN's CEO. "Also, aligning the brands, product portfolios and innovation engines of QIAGEN and Eppendorf will create a broad array of opportunities to provide significant customer benefits, such as allowing both companies to take ease-of-use and capabilities of molecular biology methods to new levels."
 
Terms of the Eppendorf reagent transaction were not disclosed, but QIAGEN expects the business to add $6 million in net sales in 2006 and $11 million in 2007.
 
"Both brands are each considered to be leading brands in their respective markets and are in leagues of their own in terms of reliability and quality," says Klaus Fink, Eppendorf's CEO. "Eppendorf's brand reaches into many areas of science whereas QIAGEN is heavily focused on life science research, applied molecular testing and molecular diagnostics. We believe that this alliance with QIAGEN has the potential to significantly increase the value proposition of Eppendorf products in those areas. Together, our brands address entire workflows with instrumentation as well as consumables and cover the core processes of laboratories employing molecular biology methods."

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue